Abstract
The dominant hormone regulating metabolic homeostasis and the switch between the anabolic and catabolic states is insulin. At the cellular level, the action of insulin and the closely related insulin-like growth factors (IGF)-1 and -2, are mediated through a complex network of diverging and converging events (reviewed in [1]). The insulin and IGF-1 receptors (IR and IGF-1R) are members of the family of receptor tyrosine kinases. Following hormone binding, these receptors undergo autophosphorylation, which activates the kinase toward other substrates termed the insulin receptor substrate (IRS) proteins. In contrast to most other tyrosine kinase receptors, it is the phosphorylated IRS proteins, rather than the receptors themselves, that link the action of these hormones to two main signaling pathways: the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAP kinase pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation (reviewed in [2]) (Fig. 2.1).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85–96
Avruch J (1998) Insulin signal transduction through protein kinase cascades. Mol Cell Biochem 182:31–48
Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB et al (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300:2754–2764
Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J et al (2009) Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 373:1083–1096
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578
Vairaktaris E, Spyridonidou S, Goutzanis L, Vylliotis A, Lazaris A et al (2007) Diabetes and oral oncogenesis. Anticancer Res 27:4185–4193
Wunderlich FT, Luedde T, Singer S, Schmidt-Supprian M, Baumgartl J et al (2008) Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proc Natl Acad Sci USA 105:1297–1302
Zhang B, Roth RA (1992) The insulin receptor-related receptor. Tissue expression, ligand binding specificity, and signaling capabilities. J Biol Chem 267:18320–18328
Becker AB, Roth RA (1990) Insulin receptor structure and function in normal and pathological conditions. Annu Rev Med 41:99–115
Hedo JA, Kahn CR, Hayashi M, Yamada KM, Kasuga M (1983) Biosynthesis and glycosylation of the insulin receptor. Evidence for a single polypeptide precursor of the two major subunits. J Biol Chem 258:10020–10026
Baron V, Kaliman P, Gautier N, Van Obberghen E (1992) The insulin receptor activation process involves localized conformational changes. J Biol Chem 267:23290–23294
Ablooglu AJ, Kohanski RA (2001) Activation of the insulin receptor’s kinase domain changes the rate-determining step of substrate phosphorylation. Biochemistry 40:504–513
Goren HJ, White MF, Kahn CR (1987) Separate domains of the insulin receptor contain sites of autophosphorylation and tyrosine kinase activity. Biochemistry 26:2374–2382
Desbois-Mouthon C, Sert-Langeron C, Magre J, Oreal E, Blivet MJ et al (1996) Deletion of Asn281 in the alpha-subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization. J Clin Endocrinol Metab 81:719–727
Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S et al (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283:1544–1548
Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL et al (2000) Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 20:5479–5489
Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE et al (2002) PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci USA 99:11357–11362
Rondinone CM, Trevillyan JM, Clampit J, Gum RJ, Berg C et al (2002) Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes 51:2405–2411
Gum RJ, Gaede LL, Koterski SL, Heindel M, Clampit JE et al (2003) Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 52:21–28
Ueki K, Kondo T, Tseng YH, Kahn CR (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 101:10422–10427
Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434–5446
Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D et al (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15958–15991
Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K et al (2001) SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276:47944–47949
Wick KR, Werner ED, Langlais P, Ramos FJ, Dong LQ et al (2003) Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2 with the insulin receptor. J Biol Chem 278:8460–8467
Dong H, Maddux BA, Altomonte J, Meseck M, Accili D et al (2005) Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. Diabetes 54:367–372
Sutherland KD, Lindeman GJ, Visvader JE (2007) Knocking off SOCS genes in the mammary gland. Cell Cycle 6:799–803
McClain DA (1992) Mechanism and role of insulin receptor endocytosis. Am J Med Sci 304:192–201
Friedman JE, Ishizuka T, Liu S, Farrell CJ, Bedol D et al (1997) Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am J Physiol 273:E1014–E1023
Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R (1997) Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 109:565–571
Sesti G, Tullio AN, D’Alfonso R, Napolitano ML, Marini MA et al (1994) Tissue-specific expression of two alternatively spliced isoforms of the human insulin receptor protein. Acta Diabetol 31:59–65
Pashmforoush M, Yoshimasa Y, Steiner DF (1994) Exon 11 enhances insulin binding affinity and tyrosine kinase activity of the human insulin proreceptor. J Biol Chem 269:32639–32648
Vogt B, Carrascosa JM, Ermel B, Ullrich A, Haring HU (1991) The two isotypes of the human insulin receptor (HIR-A and HIR-B) follow different internalization kinetics. Biochem Biophys Res Commun 177:1013–1018
Kosaki A, Pillay TS, Xu L, Webster NJ (1995) The B isoform of the insulin receptor signals more efficiently than the A isoform in HepG2 cells. J Biol Chem 270:20816–20823
Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R et al (1999) Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278–3288
Yamaguchi Y, Flier JS, Yokota A, Benecke H, Backer JM et al (1991) Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 129:2058–2066
Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R et al (2002) A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87:245–254
Leibiger B, Leibiger IB, Moede T, Kemper S, Kulkarni RN et al (2001) Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells. Mol Cell 7:559–570
Ohlsson C, Kley N, Werner H, LeRoith D (1998) p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 139:1101–1107
Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G et al (2000) Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res 60:5278–5283
Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S et al (2008) The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114:23–37
Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E et al (1991) Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352:73–77
Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG Jr et al (1995) Role of IRS-2 in insulin and cytokine signalling. Nature 377:173–177
Lavan BE, Lane WS, Lienhard GE (1997) The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem 272:11439–11443
Fantin VR, Sparling JD, Slot JW, Keller SR, Lienhard GE et al (1998) Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells. J Biol Chem 273:10726–10732
Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE (2003) Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. J Biol Chem 278:25323–25330
Lehr S, Kotzka J, Herkner A, Sikmann A, Meyer HE et al (2000) Identification of major tyrosine phosphorylation sites in the human insulin receptor substrate Gab-1 by insulin receptor kinase in vitro. Biochemistry 39:10898–10907
Wick MJ, Dong LQ, Hu D, Langlais P, Liu F (2001) Insulin receptor-mediated p62dok tyrosine phosphorylation at residues 362 and 398 plays distinct roles for binding GTPase-activating protein and Nck and is essential for inhibiting insulin-stimulated activation of Ras and Akt. J Biol Chem 276:42843–42850
Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S et al (2000) CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407:202–207
Gustafson TA, He W, Craparo A, Schaub CD, O’Neill TJ (1995) Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Mol Cell Biol 15:2500–2508
Björnholm M, He AR, Attersand A, Lake S, Liu SC et al (2002) Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans. Diabetologia 45:1697–702
Virkamaki A, Ueki K, Kahn CR (1999) Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931–943
Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M et al (1993) The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 12:1929–1936
Myers MG Jr, Mendez R, Shi P, Pierce JH, Rhoads R et al (1998) The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling. J Biol Chem 273:26908–26914
Sun XJ, Pons S, Asano T, Myers MG Jr, Glasheen E et al (1996) The Fyn tyrosine kinase binds Irs-1 and forms a distinct signaling complex during insulin stimulation. J Biol Chem 271:10583–10587
Algenstaedt P, Antonetti DA, Yaffe MB, Kahn CR (1997) Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart. J Biol Chem 272:23696–23702
Fei ZL, D’Ambrosio C, Li S, Surmacz E, Baserga R (1995) Association of insulin receptor substrate 1 with simian virus 40 large T antigen. Mol Cell Biol 15:4232–4239
Zick Y (2005) Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE 2005(268):pe4
Li J, DeFea K, Roth RA (1999) Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. J Biol Chem 274:9351–9356
Bard-Chapeau EA, Hevener AL, Long S, Zhang EE, Olefsky JM et al (2005) Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action. Nat Med 11:567–571
Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S et al (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166:213–223
Aguirre V, Uchida T, Yenush L, Davis R, White MF (2000) The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275:9047–9054
Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT et al (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333–336
Werner ED, Lee J, Hansen L, Yuan M, Shoelson SE (2004) Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J Biol Chem 279:35298–35305
Craparo A, Freund R, Gustafson TA (1997) 14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner. J Biol Chem 272:11663–11669
Tirosh A, Potashnik R, Bashan N, Rudich A (1999) Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem 274:10595–10602
Pederson TM, Kramer DL, Rondinone CM (2001) Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes 50:24–31
Giraud J, Leshan R, Lee YH, White MF (2004) Nutrient-dependent and insulin-stimulated phosphorylation of insulin receptor substrate-1 on serine 302 correlates with increased insulin signaling. J Biol Chem 279:3447–3454
Furukawa N, Ongusaha P, Jahng WJ, Araki K, Choi CS et al (2005) Role of Rho-kinase in regulation of insulin action and glucose homeostasis. Cell Metab 2:119–129
Paz K, Liu YF, Shorer H, Hemi R, LeRoith D et al (1999) Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem 274:28816–28822
Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P et al (2001) Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 15:2099–2111
Araki E, Lipes MA, Patti M-E, Bruning JC, Haag BL III et al (1994) Alternative pathway of insulin signlaing in targeted disruption of the IRS-1 gene. Nature 372:186–190
Kubota N, Terauchi Y, Tobe K, Yano W, Suzuki R et al (2004) Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 114:917–927
Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM et al (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900–904
Tseng YH, Butte AJ, Kokkotou E, Yechoor VK, Taniguchi CM et al (2005) Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin. Nat Cell Biol 7:601–611
Miki H, Yamauchi T, Suzuki R, Komeda K, Tsuchida A et al (2001) Essential role of insulin receptor substrate 1 (IRS-1) and IRS-2 in adipocyte differentiation. Mol Cell Biol 21:2521–2532
Chang Q, Li Y, White MF, Fletcher JA, Xiao S (2002) Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res 62:6035–6038
Koda M, Sulkowska M, Kanczuga-Koda L, Sulkowski S (2005) Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases. J Clin Pathol 58:645–649
Jackson JG, White MF, Yee D (1998) Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 273:9994–10003
Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C et al (1997) Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3:103–109
Dearth RK, Cui X, Kim HJ, Kuiatse I, Lawrence NA et al (2006) Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol 26:9302–9314
Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL et al (2005) Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res 65:9164–9168
Longato L, de la Monte S, Kuzushita N, Horimoto M, Rogers AB et al (2009) Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 49:1935–1943
Tanaka S, Wands JR (1996) Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 56:3391–3394
Boissan M, Beurel E, Wendum D, Rey C, Lecluse Y et al (2005) Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 167:869–877
Tanaka S, Wands JR (1996) A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J Clin Invest 98:2100–2108
Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI et al (2008) Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance. Breast Cancer Res Treat 111:79–91
Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516
Guix M, Faber AC, Wang SE, Olivares MG, Song Y et al (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118:2609–2619
Nagle JA, Ma Z, Byrne MA, White MF, Shaw LM (2004) Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 24:9726–9735
Szabolcs M, Keniry M, Simpson L, Reid LJ, Koujak S et al (2009) Irs2 inactivation suppresses tumor progression in Pten+/- mice. Am J Pathol 174:276–286
Laustsen PG, Michael MD, Crute BE, Cohen SE, Ueki K et al (2002) Lipoatrophic diabetes in Irs1(−/−)/Irs3(−/−) double knockout mice. Genes Dev 16:3213–3222
Karrman K, Kjeldsen E, Lassen C, Isaksson M, Davidsson J et al (2009) The t(X;7)(q22;q34) in paediatric T-cell acute lymphoblastic leukaemia results in overexpression of the insulin receptor substrate 4 gene through illegitimate recombination with the T-cell receptor beta locus. Br J Haematol 144:546–551
Fantin VR, Wang Q, Lienhard GE, Keller SR (2000) Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis. Am J Physiol Endocrinol Metab 278:E127–E133
Taniguchi CM, Ueki K, Kahn R (2005) Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 115:718–727
Sun XJ, Pons S, Wang LM, Zhang Y, Yenush L et al (1997) The IRS-2 gene on murine chromosome 8 encodes a unique signaling adapter for insulin and cytokine action. Mol Endocrinol 11:251–262
Inoue G, Cheatham B, Emkey R, Kahn CR (1998) Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2. J Biol Chem 273:11548–11555
Sun H, Tu X, Prisco M, Wu A, Casiburi I et al (2003) Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2. Mol Endocrinol 17:472–486
Ogihara T, Shin BC, Anai M, Katagiri H, Inukai K et al (1997) Insulin receptor substrate (IRS)-2 is dephosphorylated more rapidly than IRS-1 via its association with phosphatidylinositol 3-kinase in skeletal muscle cells. J Biol Chem 272:12868–12873
Sawka-Verhelle D, Tartare-Deckert S, White MF, Van Obberghen E (1996) Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591–786. J Biol Chem 271:5980–5983
D’Ambrosio C, Keller SR, Morrione A, Lienhard GE, Baserga R et al (1995) Transforming potential of the insulin receptor substrate 1. Cell Growth Differ 6:557–562
DeAngelis T, Chen J, Wu A, Prisco M, Baserga R (2006) Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling. Oncogene 25:32–42
Tseng YH, Kriauciunas KM, Kokkotou E, Kahn CR (2004) Differential roles of insulin receptor substrates in brown adipocyte differentiation. Mol Cell Biol 24:1918–1929
Myers MG Jr, Backer JM, Sun XJ, Shoelson S, Hu P et al (1992) IRS-1 activates phosphatidylinositol 3′-kinase by associating with src homology 2 domains of p85. Proc Natl Acad Sci USA 89:10350–10354
Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J et al (1994) Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp 70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 14:4902–4911
Shepherd PR, Withers DJ, Siddle K (1998) Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 333(Pt 3):471–490
Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR et al (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7:261–269
Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P et al (1998) Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281:2042–2045
Woodgett JR (2005) Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17:150–157
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101
Maehama T, Dixon JE (1999) PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 9:125–128
Nakashima N, Sharma PM, Imamura T, Bookstein R, Olefsky JM (2000) The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes. J Biol Chem 275:12889–12895
Yao YJ, Ping XL, Zhang H, Chen FF, Lee PK et al (1999) PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 18:3181–3185
Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M et al (2008) Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48:83–90
Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH et al (1997) P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 94:4330–4335
Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I et al (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527–532
Rizo J, Sudhof TC (1998) C2-domains, structure and function of a universal Ca2+-binding domain. J Biol Chem 273:15879–15882
Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE et al (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318:1744–1748
Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA et al (1998) Regulation of the p85/p110 phosphatidylinositol 3’-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18:1379–1387
Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A et al (1997) Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276:1848–1850
Zhao JJ, Liu Z, Wang L, Shin E, Loda MF et al (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102:18443–18448
Miyake T, Yoshino K, Enomoto T, Takata T, Ugaki H et al (2008) PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett 261:120–126
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554
Wu G, Xing M, Mambo E, Huang X, Liu J et al (2005) Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7:R609–R616
Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678–7681
Zhang A, Maner S, Betz R, Angstrom T, Stendahl U et al (2002) Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer 101:427–433
Lee JW, Soung YH, Kim SY, Lee HW, Park WS et al (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24:1477–1480
Guo XN, Rajput A, Rose R, Hauser J, Beko A et al (2007) Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer Res 67:5851–5858
McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068
Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M et al (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317:239–242
Denley A, Kang S, Karst U, Vogt PK (2008) Oncogenic signaling of class I PI3K isoforms. Oncogene 27:2561–2574
Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351–1356
Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S et al (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441:366–370
Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL (1999) Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 274:10963–10968
Bi L, Okabe I, Bernard DJ, Nussbaum RL (2002) Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 13:169–172
Asano T, Kanda A, Katagiri H, Nawano M, Ogihara T et al (2000) p110beta is up-regulated during differentiation of 3T3-L1 cells and contributes to the highly insulin-responsive glucose transport activity. J Biol Chem 275:17671–17676
Siddhanta U, McIlroy J, Shah A, Zhang Y, Backer JM (1998) Distinct roles for the p110alpha and hVPS34 phosphatidylinositol 3’-kinases in vesicular trafficking, regulation of the actin cytoskeleton, and mitogenesis. J Cell Biol 143:1647–1659
Jia S, Liu Z, Zhang S, Liu P, Zhang L et al (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454:776–779
Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD et al (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733–747
Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ et al (2008) Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453:662–666
Wee S, Wiederschain D, Maira SM, Loo A, Miller C et al (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 105:13057–13062
Luo J, Cantley LC (2005) The negative regulation of phosphoinositide 3-kinase signaling by p85 and it’s implication in cancer. Cell Cycle 4:1309–1312
Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–619
Antonetti DA, Algenstaedt P, Kahn CR (1996) Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain. Mol Cell Biol 16:2195–2203
Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM et al (2002) Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 99:419–424
Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B (2007) Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci USA 104:7809–7814
Zhang L, Huang J, Yang N, Greshock J, Liang S et al (2007) Integrative genomic analysis of phosphatidylinositol 3’-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 13:5314–5321
Shekar SC, Wu H, Fu Z, Yip SC, Nagajyothi F et al (2005) Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem 280:27850–27855
Jimenez C, Jones DR, Rodriguez-Viciana P, Gonzalez-Garcia A, Leonardo E et al (1998) Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J 17:743–753
Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP et al (2001) The phosphatidylinositol 3’-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61:7426–7429
Almind K, Delahaye L, Hansen T, Van Obberghen E, Pedersen O et al (2002) Characterization of the Met326Ile variant of phosphatidylinositol 3-kinase p85alpha. Proc Natl Acad Sci USA 99:2124–2128
Li L, Plummer SJ, Thompson CL, Tucker TC, Casey G (2008) Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin Cancer Res 14:633–637
Richard F, Pacyna-Gengelbach M, Schluns K, Fleige B, Winzer KJ et al (2000) Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 89:305–310
Tavassoli M, Steingrimsdottir H, Pierce E, Jiang X, Alagoz M et al (1996) Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21. Br J Cancer 74:115–119
Roque L, Rodrigues R, Pinto A, Moura-Nunes V, Soares J (2003) Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas. Genes Chromosom Cancer 36:292–302
Achille A, Baron A, Zamboni G, Di Pace C, Orlandini S et al (1998) Chromosome 5 allelic losses are early events in tumours of the papilla of Vater and occur at sites similar to those of gastric cancer. Br J Cancer 78:1653–1660
Katoh H, Shibata T, Kokubu A, Ojima H, Loukopoulos P et al (2005) Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J Hepatol 43:863–874
Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K et al (2002) Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 109:141–149
Taniguchi CM, Tran TT, Kondo T, Luo J, Ueki K et al (2006) Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci USA 103:12093–12097
Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S et al (2005) Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 102:10238–10243
Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC et al (2002) Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 22:965–977
Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ et al (2005) Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem 280:37489–37494
Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC (2005) The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol 170(3):455–464
Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928
Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497–5510
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Taniguchi, C.M., Kahn, C.R. (2011). Insulin/IGF-1 Signaling Nodes and their Role in Carcinogenesis. In: Fantus, I. (eds) Insulin Resistance and Cancer. Energy Balance and Cancer, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9911-5_2
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9911-5_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-9910-8
Online ISBN: 978-1-4419-9911-5
eBook Packages: MedicineMedicine (R0)